Bone Biologics received Human Research Ethics Committee approval for the first center of a multicenter pilot clinical trial to evaluate NB1 recombinant human protein growth factor (NELL-1/DBX®) in 30 patients in Australia. The study will examine the treatment of one-level degenerative disc disease in patients who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level who undergo transforaminal lumbar interbody fusion.
The study design has been reviewed by FDA in a Pre-submission, and is intended to support a pivotal clinical study in the U.S.
Bone Biologics received Human Research Ethics Committee approval for the first center of a multicenter pilot clinical trial to evaluate NB1 recombinant human protein growth factor (NELL-1/DBX®) in 30 patients in Australia. The study will examine the treatment of one-level degenerative disc disease in patients who may also have up to Grade 1...
Bone Biologics received Human Research Ethics Committee approval for the first center of a multicenter pilot clinical trial to evaluate NB1 recombinant human protein growth factor (NELL-1/DBX®) in 30 patients in Australia. The study will examine the treatment of one-level degenerative disc disease in patients who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level who undergo transforaminal lumbar interbody fusion.
The study design has been reviewed by FDA in a Pre-submission, and is intended to support a pivotal clinical study in the U.S.
Copy to clipboard 
